Related Experiment Video

Updated: Aug 7, 2026

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
08:34

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages

Published on: February 22, 2017

Modulation of LPS-, PHA- and M. tuberculosis-mediated cytokine production by pentoxifylline and thalidomide

R van Crevel1, A G Vonk, M G Netea

  • 1Department of Internal Medicine, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

European Cytokine Network
|December 23, 2000
PubMed

Insights

Pentoxifylline and thalidomide together additively inhibit tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interferon-gamma (IFN-gamma) production. This combination may offer a better efficacy-toxicity balance than monotherapy for cytokine-related diseases.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Pentoxifylline and thalidomide are known to reduce tumor necrosis factor-alpha (TNF-alpha) production.
  • Their combined effects and modulation of other cytokines remain largely uncharacterized.

Purpose of the Study:

  • To investigate the in vitro effects of pentoxifylline and thalidomide, alone and in combination, on cytokine production.
  • To assess potential synergism and modulation of inflammatory and anti-inflammatory cytokines.

Main Methods:

  • Human blood mononuclear cells were stimulated in vitro.
  • Cytokine production (TNF-alpha, IL-1 beta, IFN-gamma) was measured with and without pentoxifylline and thalidomide.
  • Different stimuli, including Mycobacterium tuberculosis, were employed.

Main Results:

  • Both pentoxifylline and thalidomide inhibited TNF-alpha, IL-1 beta, and IFN-gamma production.
  • The combination demonstrated additive, but not synergistic, inhibition.
  • No significant modulation of anti-inflammatory cytokines was observed.
  • Cytokine modulation patterns were consistent across different stimuli.

Conclusions:

  • Pentoxifylline and thalidomide exhibit additive inhibitory effects on key pro-inflammatory cytokines.
  • Combined use may improve the therapeutic index compared to individual agents.
  • Further clinical studies are warranted to validate these findings for anti-cytokine therapies.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...